Higher BMI = Less Neutropenia With CDK4/6 Inhibitor for Early Breast Cancer
A higher body mass index (BMI) translated into less neutropenia and fewer discontinuations among women with early hormone receptor (HR)-positive breast cancer treated with a CDK4/6 inhibitor, a secondary analysis of the randomized trial PALLAS showed. Among patients who received palbociclib (Ibrance) in addition to endocrine therapy, increasing BMI was associated with a small but […]